|Budget Amount *help
¥18,980,000 (Direct Cost: ¥14,600,000、Indirect Cost: ¥4,380,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2008: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2007: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
This study was planned to clarify the mechanism of CB1 activation-induced analgesia the analgesic effects of CB1 on bone cancer pain. Immunohistochemical experiments showed that, although mu opioid receptor 1 expression was reduced in the superficial dorsal horn, CB1 expression was preserved. In addition, CB1 was mainly expressed in the axon terminals of spinal excitatory interneurons. Spinal CB1 activation reduced bone cancer-related pain behaviors, including behaviors related to spontaneous pain and movement-evoked pain. Spinal CB1 activation reduced bone cancer-related pain behavior. Presynaptic inhibition may contribute to the analgesic effects of spinal CB1 activation. These findings may lead to novel strategies for the treatment of bone cancer pain.